Biomedical subjects

Ron S Sloboda

Publications and source records attributed to Ron S Sloboda.

7 recordsLinked to original sources

PubMed2005

The importance of urethra visualization for preplanned permanent prostate implants.

PURPOSE: To assess the potential consequences of using a surrogate urethra on urethral dose estimates in preplanned 125I prostate implants. METHODS AND MATERIALS: For n=220 patients, the A-P and L-R extents of prostate and urethra contours were measured in transrectal ultrasound images. Treatment plans were then developed for 6 patients, of which 5 had atypical urethral positions. For each patient, three plan variations were made using the visualized and two different surrogate urethra contours. RESULTS: The urethra typically remains fixed in the L-R direction and extends slightly below midgland, but may veer off-center and can come within 0.5 cm of the posterior surface of the prostate. Use of a surrogate urethra can potentially result in up to 30% of the urethra receiving doses exceeding a planned limit of 1.5 x 145 Gy over a contiguous length of 2.0 cm. CONCLUSIONS: The urethra should be visualized for preplanning purposes, because unintended urethral doses arising from the use of a surrogate urethra can approach levels associated with late urinary morbidity. Visualization is also essential in the postimplant setting for accurate collection of dose-toxicity data.

Body Burden↗

PubMed2004

Quality assurance measurements of a-Si EPID performance.

The performance stability of a Varian aS500 amorphous silicon (a-Si) electronic portal imaging device (EPID) was monitored over an 18-month period using a variety of standard quality assurance (QA) tests. The tests were selected to provide ongoing information about image quality and dose response from the time of EPID acceptance into clinical service. To evaluate imaging performance, we made spatial resolution and contrast measurements using both PortalVision and QC-3V phantoms for 6- and 15-MV photon beams at repetition rates of 100, 300, and 400 MU/min in standard scanning mode. To assess operational stability for dosimetry applications, we measured central axis radiation response and beam pulse variability for the same image acquisition modes. Using the QC-3V phantom, values for the critical frequency of 0.435 +/- 0.005 lp/mm for 6 MV and 0.382 +/- 0.003 lp/mm for 15 MV were obtained. The contrast-to-noise ratio was found to be approximately 20% higher for the lower photon energy. Beam pulse variability remained within the tolerance of 3% set by the manufacturer. The central axis pixel response of the EPID remained constant within +/-1% over a 5-month period for the 6-MV beam, but fell approximately 4% over the same period for the 15-MV beam. The Varian aS500 EPID studied exhibited consistent image quality and a stable radiation response. These characteristics render it suitable for quantitative applications such as clinical dose measurement.

Calibration↗

PubMed2004

Compensator thickness verification using an a-Si EPID.

Electronic portal imaging devices (EPIDs) are being increasingly employed to make therapy verification and dose measurements in the clinic. In this work, we investigate the use of an amorphous silicon (a-Si) EPID to verify the accuracy of compensator fabrication and mounting. Compensator thickness estimates on a two-dimensional grid were calculated from the primary component of transmission obtained by subtracting a modeled scatter component from the total transmission measured with the EPID. The primary component was related to the thickness via an exponential relation that includes beam hardening. Implementation of the method involved determination of: (i) a calibration curve relating EPID pixel values to energy fluence for open and attenuated fields, which was found to be linear for open fields but to have a small quadratic component for attenuated beams; (ii) EPID scatter factors to account for field size effects, which exhibited a small dependence on compensator thickness and field size; (iii) the attenuation coefficient of the steel shot compensator material, which varied slightly with off-axis distance and field size, and (iv) an analytical model to predict scatter from the compensator, which was calculated to be <4% at the standard EPID imaging distance of 140 cm. Thickness distributions were then measured for several types of attenuators including flat, test, and clinical compensators. Although uncertainties associated with compensator manufacturing were non-negligible and made assessment of thickness measurement uncertainty difficult, we estimate the latter to be approximately 0.5 mm for steel shot compensators of thickness <4 cm.

Algorithms↗

PubMed2003

Is there a preferred strength for regularly spaced 125I seeds in inverse-planned prostate implants?

PURPOSE: To determine whether a preferred seed strength exists for 125I prostate implants preplanned using a fixed intraneedle seed spacing of 1 cm and an objective needle placement strategy within the planning target volume (PTV), and incorporating explicit dose-volume constraints for the PTV and tissues at risk. METHODS AND MATERIALS: Prostate, urethra, and rectum contours for 10 patients were obtained from transrectal ultrasound studies. The PTV was defined in accordance with Radiation Therapy Oncology Group (RTOG) 0019 protocol. Inverse planning software was used to optimally arrange seeds of strength 0.3-0.8 U to cover the PTV to D(Rx) = 145 Gy, and limit urethra and rectum doses to 150% and 100% of D(Rx), respectively. Isodose distributions and dosimetric indices were calculated: V(200), V(150), V(100), V(90), D(100), D(90) for PTV; V(150) for urethra; and V(100) for rectum. For seeds of strength 0.414 and 0.6 U and three prostate sizes, the sensitivity of V(90) and D(90) to elementary perturbations of the optimal seed arrangement were examined. RESULTS: For our planning scenario, 125I seeds of strength 0.5-0.6 U provided the best possible PTV coverage while maintaining V(200) at approximately 25%. The source arrangement for 0.6-U seeds was only modestly more sensitive to perturbations than that for 0.414-U seeds. These findings may not be applicable to implants planned manually or that involve needle placement outside the PTV. CONCLUSION: Given a particular source arrangement, inverse planning aimed at maximizing dosimetric coverage of the prostate while limiting doses to the urethra and rectum can be used to search for a preferred seed strength. For regularly spaced sources within the PTV, higher strength seeds can provide better dose coverage and better urethral protection than lower strength seeds.

Brachytherapy↗

PubMed2003

Dosimetric consequences of increased seed strength for I-125 prostate implants.

Based on the findings of an earlier planning study, we compared post-implant dose distributions for two groups of 20 consecutive patients treated to 145 Gy with 0.414 and 0.526 U I-125 seeds. Dosimetric coverage as measured by the key clinical index D(90) was significantly better for the higher-strength seeds, with no apparent deleterious effects.

Dose-Response Relationship, Radiation↗

PubMed2003

Compensator quality control with an amorphous silicon EPID.

The calibration and quality control of compensators is conventionally performed with an ion chamber in a water-equivalent phantom. In our center, the compensator factor and four off-axis fluence ratios are measured to verify the central axis beam modulation and orientation of the compensator. Here we report the investigation of an alternative technique for compensator quality control using an amorphous silicon electronic portal imaging device (a-Si EPID). Preliminary experiments were performed to identify appropriate EPID operating parameters for this relative dosimetric study and also to quantify EPID operation. The pixel value versus energy fluence response of the EPID for both open and compensated fields was then determined, and expressed via calibration curves. For open fields the response was seen to be linear, whereas for compensated fields it exhibited a small quadratic component. To account for field size effects, we measured EPID scatter factors. These exhibited small but non-negligible dependencies on compensator thickness and source-detector distance. Finally, a number of test and clinical compensators were evaluated to assess the suitability of the EPID for compensator quality control. Our results indicate that the a-Si EPID can measure clinical compensator factors and off-axis energy fluence ratios to within 2% of values measured by a Farmer chamber on average, and so is a suitable ion chamber replacement.

Calibration↗

PubMed2002

Monte Carlo dose parameters of the BrachySeed model LS-1 125I brachytherapy source.

Using a modified EGS4 code and associated user code DOSCGC, the two-dimensional dose rate distribution in water and air-kerma strength are calculated for a BrachySeed (model LS-1) 125I brachytherapy source, based on geometry and material data provided by the manufacturer. The AAPM TG-43 dose parameters derived from these results include the dose rate constant, the radial dose function, the anisotropy function, and the anisotropy factor and constant. The value of the dose rate constant so obtained is 0.932 +/- 0.003 cGy h(-1) U(-1). The source strength calculation excludes the contribution from titanium characteristic X-rays (4.5 and 4.9 keV) in the source in order to comply with a new primary calibration standard implemented by the National Institute of Standards and Technology in 1999. A sampling procedure for simulating silver characteristic X-ray production in the mixture material of the source core is developed in the EGS4 code. The calculated results reveal the good dose isotropy of the LS-1 source. The Monte Carlo dose parameters obtained are compared with measurements and calculations of other investigators.

Brachytherapy↗